trending Market Intelligence /marketintelligence/en/news-insights/trending/CoxFmWGDsGHh4hQvqC5M7g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Cambrex to be acquired by private equity firm in $2.4B deal

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Cambrex to be acquired by private equity firm in $2.4B deal

Life sciences company Cambrex Corp. agreed to be acquired by an affiliate of London-based private equity firm Permira Advisers Ltd. for $60 per share in cash.

Including Cambrex's net debt, the transaction is valued at about $2.4 billion. The offer price represents a 47.1% premium to the company's closing price Aug. 6. The company's shares were up 46.84% to $59.88 in pre-market trading Aug. 6 after the deal announcement.

The agreement includes a 45-day go-shop period during which Cambrex may actively solicit acquisition proposals from third parties.

Permira plans to finance the transaction through a combination of debt and equity financing.

Completion of the deal is expected to occur in the fourth quarter subject to customary closing conditions, including approvals from Cambrex shareholders and customary regulatory authorities.

East Rutherford, N.J.-based Cambrex offers drug substance, drug product and analytical services for the small molecule industry.

Morgan Stanley & Co. LLC is acting as exclusive financial adviser to Cambrex, with Kirkland & Ellis LLP as legal adviser. RBC Capital Markets is serving as exclusive financial adviser, and provided committed debt financing to the Permira funds, while Skadden Arps Slate Meagher & Flom LLP is serving as legal adviser to the funds.